Clinical trials: Drug Drug Interaction (DDI)
Diabetes Mellitus, Type II
CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)
The purpose of this study is to evaluate a pharmacokinetic drug interaction between lobeglitazone and sitagliptin in healthy male volunteers.
- Trial name
- NCT02824874
- Testing
- Duvie Tab. 0.5mg, Duvie Tab. 0.5mg + Januvia Tab. 100mg
- Where
- South Korea
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Healthy Volunteers
Dexpramipexole and Warfarin Drug Drug Interaction (DDI) Study
This study will assess the effect of dexpramipexole on the pharmacokinetics (PK) of the CYP2C9 probe substrate warfarin in healthy volunteers.
- Trial name
- NCT01597310
- Testing
- Warfarin, Dexpramipexole
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Idiopathic Pulmonary Fibrosis
Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects
A single-center, open-label study designed to assess the drug-drug interaction of HEC585 and pirfenidone in healthy male and female subjects.
- Trial name
- NCT07588646
- Testing
- HEC585, Nintedanib, Pirfenidone
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Alzheimer Disease
Drug-Drug Interaction (DDI) w/Ketoconazole or Fluconazole
The purpose of the study is to determine if the concomitant administration of either ketoconazole or fluconazole with BMS-708163 will affect the PK of BMS-708163 and to assess safety and tolerability of BMS-708163
- Trial name
- NCT00860275
- Testing
- BMS-708163, BMS-708163 + Ketoconazole, Ketoconazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals
To evaluate the safety and tolerance of concurrent administration of standard-dose didanosine (ddI) with low-dose ribavirin in HIV-positive patients.
- Trial name
- NCT00000772
- Testing
- Ribavirin, Didanosine
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
Phase 1 Study of DDI Between DW330SR and DW1030 in Healthy Male Subjects
The purpose of this study is to evaluate drugs interactions to compare pharmacokinetics in groups of monotherapy DW330SR, monotherapy DW1030, and coadministration DW330SR and DW1030
- Trial name
- NCT02071381
- Testing
- DW330SR 45mg, DW1030 75mg
- Where
- South Korea
- Sponsor
- Daewon Pharmaceutical Co., Ltd.
Healthy Volunteers
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
The purpose of this study is to assess the drug-drug interaction (DDI) of repinatrabit with ethinyl estradiol/norethindrone or norethisterone (EE/NE), metformin, rosuvastatin, carbamazepine, and methotrexate in healthy…
- Trial name
- NCT07446400
- Testing
- Repinatrabit, EE/NE, Metformin
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Drug Drug Interaction
The Potential of Givinostat as DDI Victim in Co-administration P-gp Inhibitor (Part 2)
Primary objective: To assess the potential effect of oral Clarithromycin on the single-dose pharmacokinetics of Givinostat. Secondary objective: To assess the safety and tolerability of concomitant administration of Givinostat…
- Trial name
- NCT05845567
- Testing
- Givinostat, Clarithromycin
- Where
- Portugal
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Italfarmaco
Diabetic Neuropathies, Diabetic Neuropathy Peripheral
A Study Evaluating Drug-Drug Interaction (DDI) Between HSK16149 Capsules and Metformin Hydrochloride Tablets
This study is a single-center, open, single-arm study, conducted in healthy Chinese populations, and plans to enroll 22 healthy adult subjects (the ratio of either sex is not less than 1/3).
- Trial name
- NCT04841720
- Testing
- HSK16149, Metformin Hydrochloride tablet, HSK16149+Metformin（phase 3）
- Where
- China
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Amyotrophic Lateral Sclerosis
Dexpramipexole and Cimetidine Drug Drug Interaction (DDI)
This study will assess the effect of cimetidine on the pharmacokinetics (PK) of dexpramipexole in healthy volunteer and evaluate the safety and tolerability of dexpramipexole when given with or without cimetidine.
- Trial name
- NCT01536249
- Testing
- Dexpramipexole, Cimetidine plus Dexpramipexole
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Knopp Biosciences
Type 2 Diabetes
The DDI Study of SP2086 and Simvastatin
The purpose of the study is to investigate the potential interaction between multiple oral doses of SP2086 and a single oral dose of Simvastatin in healthy adult volunteers.
- Trial name
- NCT02817243
- Testing
- SP2086, Simvastatin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib…
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor
- Trial name
- STELLAR-002 (NCT05176483)
- Testing
- Zanzalintinib, Nivolumab, Ipilimumab
- Where
- 122 sites in United States, Australia and 11 more
- Volunteers
- 1,394 people
- Sponsor
- Exelixis
Healthy
Drug-Drug Interaction (DDI) Study of ALXN2050 in Healthy Adult Participants
This study will evaluate the potential drug interactions between ALXN2050 and cyclosporine (Part 1), between ALXN2050 and tacrolimus (Part 2), and between ALXN2050 and mycophenolate mofetil (MMF) (Part 3).
- Trial name
- NCT05202145
- Testing
- ALXN2050, Cyclosporine, Tacrolimus
- Where
- United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Alexion Pharmaceuticals, Inc.
Advanced Malignancies
A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies
This drug-drug interaction (DDI) study aims to evaluate the impact of pelabresib at steady-state plasma concentrations on the pharmacokinetic (PK) profile of A) a single dose of repaglinide and a single dose of midazolam, and B)…
- Trial name
- NCT07340190
- Testing
- pelabresib, repaglinide, midazolam
- Where
- 6 sites in France, Italy and 1 more
- Volunteers
- 24 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Subjects, Pharmacokinetics
Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects
The purpose of this study is to evaluate the effect of steady state solifenacin and mirabegron on the pharmacokinetics of co-administered steady state digoxin.
- Conditions
- Healthy Subjects, Pharmacokinetics, Drug-Drug Interaction (DDI)
- Trial name
- NCT02127034
- Testing
- Mirabegron, Solifenacin, Digoxin
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
Diabete Mellitus
Teneligliptin and Atorvastatin DDI Study
A randomized, open-label, cross-over, multiple dosing study to evaluate drug-drug interaction between Teneligliptin and Atorvastatin in healthy male adults
- Trial name
- NCT03769870
- Testing
- Teneligliptin 20mg/day, Atorvastatin 40mg/Day, Teneligliptin 20mg/day + Atorvastatin 40mg/day
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Handok Inc.
Healthy Adult Subject
A Drug-Drug Interaction (DDI) Study of HDM1002 With Rifampicin and Itraconazole in Healthy Subjects
The purpose of this study is to characterize the effect of rifampicin and itraconazole on the PK of single dose of HDM1002 in healthy adult subjects.
- Trial name
- NCT06562088
- Testing
- HDM1002 and rifampicin, HDM1002 and itraconazole
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Healthy
GLPG0259 Multiple Ascending Dose and Methotrexate Drug-drug Interaction (DDI) in Healthy Subjects
The purpose of the study is to evaluate the safety and tolerability of multiple increasing oral doses of GLPG0259 compared to placebo.
- Trial name
- NCT00989703
- Testing
- GLPG0259, Methotrexate
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV